Melanoma is the most dangerous form of skin cancer, but how bad it is depends almost entirely on when it’s caught. Detected early and still confined to the skin, melanoma has a five-year survival rate of 97.6%. Found after it has spread to distant organs, that number drops to 16.2%. That enormous gap makes melanoma a cancer where timing changes everything.
The overall five-year survival rate across all stages is 94.7%, which reflects the fact that most cases are caught early. Still, melanoma is responsible for an estimated 8,510 deaths in the U.S. in 2026 alone, making it far more lethal than the other common skin cancers (basal cell and squamous cell), which rarely spread beyond the skin.
Why Melanoma Is More Dangerous Than Other Skin Cancers
What sets melanoma apart is its ability to spread. Basal cell and squamous cell carcinomas tend to grow locally, staying in or near the skin where they started. Melanoma spreads locally, regionally to nearby lymph nodes, and distantly to organs throughout the body. The most common sites it travels to are other areas of skin and tissue just beneath it, followed by the lungs, liver, bones, and brain.
Melanoma has a particular tendency to reach the central nervous system, which makes it especially difficult to treat once it has spread widely. The blood-brain barrier, a protective layer that normally shields the brain, also blocks many cancer therapies from reaching tumors there. There are even documented cases of melanoma being transferred from organ donors to recipients years after the donor’s original diagnosis, suggesting the cancer can seed itself in distant tissues long before it becomes detectable.
How Thickness Determines Severity
When a melanoma is removed, the single most important measurement is how deep it has grown into the skin. This is called the Breslow depth, measured in millimeters from the skin surface to the deepest point of the tumor. The risk categories break down into four levels:
- 0.75 mm or less: Thin, lowest risk
- 0.76 to 1.5 mm: Intermediate
- 1.51 to 4 mm: Higher risk
- Greater than 4 mm: Highest risk
A person’s risk of the cancer spreading is directly tied to this depth and whether the surface of the tumor is ulcerated (broken open). A melanoma less than a millimeter thick that hasn’t ulcerated carries a very different prognosis than one measuring 4 mm or more. This is why dermatologists push for early checks: a thin melanoma can often be cured with surgery alone, while a thick one may have already sent cells elsewhere in the body.
Survival Rates by Stage
Stage at diagnosis is the clearest predictor of outcome. The five-year survival rates tell a stark story:
- Stage 0 (in situ, confined to the top layer of skin): 100%
- Stage I–II (localized, hasn’t spread beyond the original site): 97.6%
- Stage IV (distant spread to organs): 16.2%
The jump between localized and distant disease is one of the steepest of any cancer. For Stage II and III melanomas that are treated, recurrence remains a real concern. About 56% of Stage II patients remain relapse-free at five years, and for Stage III, that number drops to roughly 28% to 44%. Whether the cancer has reached nearby lymph nodes makes a major difference: patients with a negative lymph node biopsy have five-year recurrence-free survival of 76% to 90%, compared to 35% to 58% for those with positive nodes.
Some Types Are More Aggressive
Not all melanomas behave the same way. Acral lentiginous melanoma, the type that develops on palms, soles, and under fingernails or toenails, tends to be diagnosed later and carries a worse prognosis. Its five-year survival rate is 80.3%, compared to 91.3% for cutaneous melanoma overall. At ten years, the gap widens further: 67.5% versus 87.5%.
Part of the reason is that acral lentiginous melanoma is often thicker at the time of diagnosis. Only 41% of these tumors are caught when they’re still thin (1 mm or less), compared to 70% of standard cutaneous melanomas. Because they appear in locations people don’t routinely check, and because they’re more common in people with darker skin who may not consider themselves at risk for skin cancer, they tend to be found at a more advanced stage. Even when researchers compare tumors of the same thickness and stage, acral lentiginous melanoma still has lower survival rates, suggesting it may be biologically more aggressive as well.
Sunburns and Risk
Sun exposure is the most modifiable risk factor for melanoma, and the data on sunburns is striking. A large meta-analysis found that people who experienced sunburns during childhood had roughly 91% higher odds of developing melanoma compared to those who didn’t. Sunburns during adolescence increased risk by 63%, and adult sunburns by 44%.
The risk also climbs with the number of burns. For every five sunburns during childhood, the odds of melanoma nearly doubled. The same pattern held for adult sunburns: five burns per decade of adult life tripled the risk. These numbers reinforce that sunburn damage accumulates over a lifetime, and that childhood burns carry the greatest weight, likely because younger skin is more vulnerable to the type of DNA damage that leads to melanoma decades later.
Treatment Has Dramatically Improved
For people diagnosed with advanced melanoma, the outlook has changed enormously in the last 15 years. Before modern immunotherapy, the median survival for patients with inoperable Stage IV disease was just six to nine months. Today, with combination immunotherapy that helps the immune system recognize and attack cancer cells, median survival has climbed to nearly six years.
That’s a tenfold improvement in the most aggressive cases. These treatments don’t work for everyone, and they can cause significant side effects as the immune system becomes more active than usual. But for a cancer that was once considered almost universally fatal once it spread, the shift has been remarkable. Long-term follow-up data shows that a meaningful percentage of patients with advanced melanoma are now living well beyond five years, something that was almost unheard of before 2011.
What Makes the Difference
Melanoma’s severity is real, but it’s not a fixed number. The same disease that kills roughly 8,500 Americans a year is also one that, when caught at Stage 0, has a 100% survival rate. The gap between best-case and worst-case outcomes is wider for melanoma than for most cancers, and it’s almost entirely determined by how early the cancer is found. A new or changing mole, a spot that looks different from the rest, or a dark streak under a nail are all worth getting checked, because thickness at diagnosis is the single factor that matters most.